Last 12 months
Inside the activity.
0 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2024 Filed Dec 17, 2024 22:21 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029631 · form4-12172024_101258.xml · derivative · entry 4 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:21 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029631 · form4-12172024_101258.xml · derivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:21 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
Exercise / conversionCommon Stock | 67,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029631 · form4-12172024_101258.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 803,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:22 UTC |
Multani Pratik SChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029633 · form4-12172024_101230.xml · derivative · entry 5 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F7 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F7 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:22 UTC |
Multani Pratik SChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029633 · form4-12172024_101230.xml · derivative · entry 4 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:22 UTC |
Multani Pratik SChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029633 · form4-12172024_101230.xml · derivative · entry 3 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:22 UTC |
Multani Pratik SChief Medical Officer
|
Exercise / conversionCommon Stock | 24,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029633 · form4-12172024_101230.xml · nonDerivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:24 UTC |
Hoerter Steven L.Director
|
GrantStock Option (right to buy) · Derivative | 25,600 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001415889-24-016909 · form4-06142024_080617.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2034-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:25 UTC |
Kunkel Lori AnneDirector
|
GrantStock Option (right to buy) · Derivative | 25,600 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001415889-24-016913 · form4-06142024_080645.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2034-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 16:22 UTC |
Dier MardiDirector
|
GrantStock Option (right to buy) · Derivative | 25,600 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001415889-24-016906 · form4-06142024_080637.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2034-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:21 UTC |
Heyman Richard A.Director
|
GrantStock Option (right to buy) · Derivative | 25,600 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001415889-24-016903 · form4-06142024_080630.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2034-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:26 UTC |
You AngieDirector
|
GrantStock Option (right to buy) · Derivative | 25,600 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001415889-24-016916 · form4-06142024_080646.xml · derivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2034-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 22:48 UTC |
Kunkel Lori AnneDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001415889-24-015475 · form4-06042024_100642.xml · derivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,200 Underlying: Common Stock · 20,500 shares Expires 2032-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: (A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 22:48 UTC |
Kunkel Lori AnneDirector
|
Exercise / conversionCommon Stock | 20,500 | $3.75 | $76,875.00 |
DisclosureSEC source: 0001415889-24-015475 · form4-06042024_100642.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:20 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
SaleCommon Stock | 40,000 | $16.21 | $648,380.00 |
DisclosureSEC source: 0001415889-24-007345 · form4-03082024_090337.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728,544 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 40,000 shares sold in the price range of $16.00 to $16.43 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 01:01 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
SaleCommon Stock | 26,042 | $12.30 | $320,186.39 |
DisclosureSEC source: 0001415889-24-003114 · form4-02092024_010219.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 768,544 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F3 · price: Represents the weighted average share price of an aggregate total of 26,042 shares sold in the price range of $12.11 to $12.40 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 01:01 UTC |
Chacko JacobDirector · PRESIDENT AND CEO
|
SaleCommon Stock | 13,958 | $12.12 | $169,159.79 |
DisclosureSEC source: 0001415889-24-003114 · form4-02092024_010219.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 794,586 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 13,958 shares sold in the price range of $12.00 to $12.31 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:18 UTC |
Piscitelli DominicChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000364 · doc4.xml · derivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:18 UTC |
Piscitelli DominicChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001209191-24-000364 · doc4.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2025, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:17 UTC |
Chacko JacobDirector · President and CEO
|
GrantRestricted Stock Unit · Derivative | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000361 · doc4.xml · derivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:17 UTC |
Chacko JacobDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 510,000 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001209191-24-000361 · doc4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 510,000 Underlying: Common Stock · 510,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2025, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:20 UTC |
Multani Pratik SChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000368 · doc4.xml · derivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:20 UTC |
Multani Pratik SChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001209191-24-000368 · doc4.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2025, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:40 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059264 · doc4.xml · derivative · entry 4 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:40 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059264 · doc4.xml · derivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,042 Underlying: Common Stock · 6,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:40 UTC |
Piscitelli DominicChief Financial Officer
|
SaleCommon Stock | 5,282 | $8.58 | $45,338.05 |
DisclosureSEC source: 0001209191-23-059264 · doc4.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,809 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 5,282 shares sold in the price range of $8.57 to $8.756 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:40 UTC |
Piscitelli DominicChief Financial Officer
|
Exercise / conversionCommon Stock | 14,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059264 · doc4.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:39 UTC |
Chacko JacobDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059263 · doc4.xml · derivative · entry 4 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 22,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:39 UTC |
Chacko JacobDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059263 · doc4.xml · derivative · entry 3 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:39 UTC |
Chacko JacobDirector · President and CEO
|
SaleCommon Stock | 14,539 | $8.58 | $124,812.95 |
DisclosureSEC source: 0001209191-23-059263 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 808,544 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 14,539 shares sold in the price range of $8.57 to $8.77 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:39 UTC |
Chacko JacobDirector · President and CEO
|
Exercise / conversionCommon Stock | 38,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059263 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 823,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes 3,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:42 UTC |
Multani Pratik SChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059266 · doc4.xml · derivative · entry 4 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:42 UTC |
Multani Pratik SChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059266 · doc4.xml · derivative · entry 3 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,042 Underlying: Common Stock · 6,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:42 UTC |
Multani Pratik SChief Medical Officer
|
SaleCommon Stock | 5,282 | $8.59 | $45,350.72 |
DisclosureSEC source: 0001209191-23-059266 · doc4.xml · nonDerivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,809 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 5,282 shares sold in the price range of $8.57 to $8.795 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:42 UTC |
Multani Pratik SChief Medical Officer
|
Exercise / conversionCommon Stock | 14,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059266 · doc4.xml · nonDerivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 01:28 UTC |
Chacko JacobDirector · President and CEO
|
SaleCommon Stock | 5,156 | $8.01 | $41,287.19 |
DisclosureSEC source: 0001209191-23-042054 · doc4.xml · nonDerivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 780,652 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F3 · price: Represents the weighted average share price of an aggregate total of 5,156 shares sold in the price range of $8.00 to $8.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 01:28 UTC |
Chacko JacobDirector · President and CEO
|
SaleCommon Stock | 10,508 | $8.01 | $84,212.16 |
DisclosureSEC source: 0001209191-23-042054 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 785,808 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 10,508 shares sold in the price range of $8.00 to $8.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:35 UTC |
Chacko JacobDirector · President and CEO
|
SaleCommon Stock | 4,336 | $8.01 | $34,710.55 |
DisclosureSEC source: 0001209191-23-041805 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 796,316 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 4,336 shares sold in the price range of $8.00 to $8.025 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 23:18 UTC |
Chacko JacobDirector · President and CEO
|
SaleCommon Stock | 20,000 | $8.03 | $160,562.00 |
DisclosureSEC source: 0001209191-23-040090 · doc4.xml · nonDerivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,652 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 28, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 20,000 shares sold in the price range of $8.00 to $8.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 4,000 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:55 UTC |
Hoerter Steven L.Director
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-23-037395 · doc4.xml · derivative · entry 1 Hoerter Steven L. · CIK 0001533451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:56 UTC |
Kunkel Lori AnneDirector
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-23-037396 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 16:52 UTC |
Dier MardiDirector
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-23-037393 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:54 UTC |
Heyman Richard A.Director
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-23-037394 · doc4.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:58 UTC |
You AngieDirector
|
GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-23-037398 · doc4.xml · derivative · entry 1 You Angie · CIK 0001647664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:11 UTC |
Piscitelli DominicChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006195 · doc4.xml · derivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:11 UTC |
Piscitelli DominicChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006195 · doc4.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:09 UTC |
Chacko JacobDirector · President and CEO
|
GrantRestricted Stock Unit · Derivative | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006191 · doc4.xml · derivative · entry 2 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:09 UTC |
Chacko JacobDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006191 · doc4.xml · derivative · entry 1 Chacko Jacob · CIK 0001608936 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:13 UTC |
Multani Pratik SChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006198 · doc4.xml · derivative · entry 2 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:13 UTC |
Multani Pratik SChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006198 · doc4.xml · derivative · entry 1 Multani Pratik S · CIK 0001586894 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.